– DENMARK, Copenhagen – Evaxion Biotech A/S, a clinical-stage biotechnology company developing AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, today announced the appointment of Marianne Søgaard as Chairwoman of its Board of Directors.
“We are very pleased to welcome Marianne Søgaard as the new Chairwoman of Evaxion. Marianne has been part of our team since 2018 and has been invaluable in the development and execution of our business model. With her extensive experience in legal affairs and technology, Marianne will provide important guidance and advice as we continue to develop our AI platforms to advance our product candidates through clinical development.” said CEO Lars Wegner.
About Marianne Søgaard
Marianne Søgaard has been an executive and most recently SVP and General Counsel at Evaxion since 2018. Before that, she served for 22 years as a lawyer and partner of the law firm Poul Schmith where she primarily focused on acquisitions of processes and technology solutions. She was also a member of the Board of Directors of Poul Schmith from 2014 to 2017. Currently, Mrs. Søgaard serves on several Boards of technology companies, including How to Robot and Altapay.
Marianne Søgaard, Chairwoman of Evaxion, said: “It is an honor to become Chairwoman of Evaxion at such an exciting point in the company’s development. Evaxion is built on technology that we believe has the potential to revolutionize how cancer and infectious diseases are treated. I look forward to working together with the team and playing my part in this journey.”
About Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion Biotech is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase 1/2 clinical development. Also, the Company is advancing a portfolio of vaccines to treat bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus, or MRSA) induced skin and soft tissue infections.
For more information: https://evaxion-biotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
